Qyuns Therapeutics (02509) disclosed a share repurchase on 26 January 2026. The company repurchased 89,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 21.32 to HKD 21.96, amounting to an aggregate consideration of HKD 1,952,769.28. These repurchased shares are designated as treasury shares, bringing the total number of treasury shares to 2,056,200.

Following the transaction, the total number of issued shares remained at 227,071,600. The shares outstanding (excluding treasury shares) now stand at 225,015,400, compared with the opening balance of 225,105,000 as of 21 January 2026.

Under the existing share repurchase mandate approved on 20 June 2025, the company is authorized to repurchase up to 22,207,160 shares. Including this latest transaction, the cumulative repurchases represent approximately 0.9259% of the total issued shares (excluding treasury shares) at the time of that resolution. The company is subject to a moratorium period until 25 February 2026 regarding any new share issuance or sales of treasury shares.